N2OFF, Inc. (NITO)

N2OFF, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

N2OFF, Inc. (NITO) is a Biotechnology company based in IL with a market capitalization of $2.9M. Free cash flow was negative at -$3.8M. This page tracks NITO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

IL · 3 employees · IPO Nov 12, 2010

Valuation

Valuation & price

$4.45as of May 17, 2026· -65.8% vs 52w high

P/E ratio

Latest-FY diluted EPS

0.18

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$13.00$6.90$0.79Jul 25Jan 26Jul 26
$0.7952-week range$13.00
Loading valuation history…

Fundamentals

Key fundamentals

$2.9M

Market cap

Revenue growth (YoY)

21.4%

Gross margin

-$3.8M

Free cash flow (USD)

-$3.3M

Net debt

Net cash position

581.1%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$322K$0

Free cash flow by year

20162025

-$651K-$3.8M

Gross margin by year

20212024

69.0%21.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: May 14, 2026 (EPS $-10.74)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

No tracked SEC signals for NITO yet — activity appears here as filings land on EDGAR.

Questions

Frequently asked questions

What is N2OFF, Inc.'s market cap?

N2OFF, Inc. (NITO) has a market capitalization of $2.9M.

What is NITO's P/E ratio?

A meaningful P/E ratio is not available for NITO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NITO's price-to-book (P/B) ratio?

NITO trades at 0.18 times book value per share.

When did N2OFF, Inc. last report earnings?

NITO last reported earnings on May 14, 2026; the next date is not yet scheduled.

Are insiders buying NITO stock?

SEC Form 4 filings show no open-market insider buys at N2OFF, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.